ArticleTherapeutic advances in medical oncology2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deep and rapid prostate-specific antigen (PSA) response is an important indicator to consider in treatment decision-making given its predictive value for long-term clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC). Objectives: This study compared early PSA90 response (⩾90% reduction in PSA levels) in a large and recent cohort of patients with mCSPC initiating apalutamide or enzalutamide in the United States. Design: A retrospective longitudinal analysis was conducted. Methods: Patients with mCSPC were identified from linked claims and electronic medical record data from the United States and categorized into the apalutamide or enzalutamide cohorts based on the first claim/dispensation on or after December 16th, 2019. To adjust for differences observed in patient characteristics between the two cohorts, inverse probability of treatment weighting was used. Weighted Cox proportional hazards models were used to compare PSA90 response (PSA measurement ⩾90% lower than the most recent pretreatment PSA value) by 6 months post treatment initiation between the apalutamide and enzalutamide cohorts. Results: Among 1296 patients with mCSPC treated with apalutamide and 1111 treated with enzalutamide, pretreatment characteristics were balanced after weighting. PSA90 response by 6 months was achieved by 61.7% of patients in the apalutamide cohort and 55.2% of patients in the enzalutamide cohort (weighted hazard ratio: 1.20 [95% confidence interval: 1.07, 1.36]; Conclusion: In a large, real-world, retrospective analysis, patients with mCSPC treated with apalutamide were associated with a significantly higher rate of early PSA90 response compared to enzalutamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.